CytoSorb® Registered and Commercially Available in Singapore
CytoSorb® Registered and Commercially Available in Singapore CytoSorbents announces immediate commercial availability of CytoSorb in Singapore through distributor Humedical News provided by Share this article MONMOUTH JUNCTION, N.J., May 25, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb® blood purification technology to treat deadly conditions in the intensive care unit (ICU) and cardiac surgery, announces that the Singapore Health Sciences Authority (HSA) has now approved registration of CytoSorb® for all equivalent Eu...
Source: prnewswire.com